Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10307028 | Psychoneuroendocrinology | 2005 | 11 Pages |
Abstract
Conclusions: At treatment entry, each of the three patient outcome groups was identified by levels of circulating DHEAS and distressed mood. In the ABST patients, distressed mood during withdrawal may have been mitigated through antidepressant-like actions of enhanced endogenous DHEAS activity, thus contributing to improved abstinence and treatment retention. Patients, such as the DO group, with high levels of distressed mood at treatment entry and low DHEAS levels may benefit from adjunctive pharmacotherapy that targets DHEAS and POMS measures. Patients, such as the REL group, who lack distressed mood at treatment entry, may require intense application of motivational approaches plus residential treatment.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
J.N. Wilkins, M.D. Majewska, W. Van Gorp, S.H. Li, C. Hinken, D. Plotkin, D. Setoda,